Last reviewed · How we verify
I-131 Metaiodobenzylguanidine
I-131 MIBG is a radioactive iodine-labeled compound that selectively accumulates in neuroendocrine tumors and delivers targeted radiation therapy to kill cancer cells.
I-131 MIBG is a radioactive iodine-labeled compound that selectively accumulates in neuroendocrine tumors and delivers targeted radiation therapy to kill cancer cells. Used for Relapsed or refractory high-risk neuroblastoma, Metastatic pheochromocytoma and paraganglioma.
At a glance
| Generic name | I-131 Metaiodobenzylguanidine |
|---|---|
| Also known as | MIBG |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Radiopharmaceutical; targeted radionuclide therapy |
| Target | Norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MIBG (metaiodobenzylguanidine) is taken up by the norepinephrine transporter on neuroendocrine tumor cells, allowing the radioactive iodine-131 to concentrate in these tumors. The beta radiation emitted by I-131 then delivers cytotoxic doses directly to the malignant cells while minimizing exposure to surrounding healthy tissue. This targeted radiopharmaceutical approach is particularly effective for neuroendocrine tumors including neuroblastoma and pheochromocytoma.
Approved indications
- Relapsed or refractory high-risk neuroblastoma
- Metastatic pheochromocytoma and paraganglioma
Common side effects
- Myelosuppression (thrombocytopenia, neutropenia, anemia)
- Nausea and vomiting
- Fatigue
- Hypothyroidism
- Salivary gland dysfunction
Key clinical trials
- Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (PHASE1)
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (PHASE2)
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
- Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (PHASE2)
- 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I-131 Metaiodobenzylguanidine CI brief — competitive landscape report
- I-131 Metaiodobenzylguanidine updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI